Aclaris Therapeutics (NASDAQ:ACRS) has received a consensus recommendation of “Hold” from the eight research firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $46.00.
A number of analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $50.00 target price on shares of Aclaris Therapeutics in a research note on Monday, March 12th. Leerink Swann decreased their target price on shares of Aclaris Therapeutics from $54.00 to $52.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 28th. BidaskClub cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 19th. Finally, Guggenheim assumed coverage on shares of Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 target price on the stock.
Get Aclaris Therapeutics alerts:
Shares of NASDAQ ACRS traded up $0.20 during midday trading on Friday, reaching $18.00. 178,120 shares of the company were exchanged, compared to its average volume of 203,301. The stock has a market cap of $556.31, a PE ratio of -7.20 and a beta of 1.63. Aclaris Therapeutics has a one year low of $16.01 and a one year high of $30.08.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.10. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.80 million. analysts expect that Aclaris Therapeutics will post -4.27 EPS for the current year.
In other Aclaris Therapeutics news, Director Stephen A. Tullman acquired 26,700 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, April 6th. The shares were bought at an average price of $16.54 per share, with a total value of $441,618.00. Following the completion of the purchase, the director now directly owns 157,507 shares in the company, valued at approximately $2,605,165.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Neal Walker acquired 10,000 shares of Aclaris Therapeutics stock in a transaction that occurred on Thursday, April 5th. The stock was acquired at an average cost of $16.75 per share, for a total transaction of $167,500.00. Following the purchase, the insider now owns 897,184 shares of the company’s stock, valued at $15,027,832. The disclosure for this purchase can be found here. In the last three months, insiders purchased 37,950 shares of company stock worth $629,856. 16.30% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. grew its stake in shares of Aclaris Therapeutics by 27.9% in the fourth quarter. Franklin Resources Inc. now owns 2,596,814 shares of the biotechnology company’s stock worth $64,037,000 after purchasing an additional 565,945 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Aclaris Therapeutics by 49.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 92,507 shares of the biotechnology company’s stock valued at $2,388,000 after buying an additional 30,742 shares during the period. Redmile Group LLC lifted its holdings in Aclaris Therapeutics by 6.0% in the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock valued at $2,639,000 after buying an additional 6,060 shares during the period. Driehaus Capital Management LLC lifted its holdings in Aclaris Therapeutics by 73.8% in the fourth quarter. Driehaus Capital Management LLC now owns 523,428 shares of the biotechnology company’s stock valued at $12,908,000 after buying an additional 222,254 shares during the period. Finally, Victory Capital Management Inc. lifted its holdings in Aclaris Therapeutics by 24.1% in the fourth quarter. Victory Capital Management Inc. now owns 73,501 shares of the biotechnology company’s stock valued at $1,813,000 after buying an additional 14,290 shares during the period. 92.32% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.